Introducing RapidCert™ Biological Indicator (BI) Sterility TestingNelson Labs’ patent-pending solution for quicker sterility confirmation. Learn More
Header Artwork
Header Artwork

LIVE WEBINAR

Ensuring Drug–Device Compatibility: Foundations for Safe and Effective Combination Products

May 14, 2026

2:00 pm ET

Tonya Morris and Mark Guevarra

As combination products continue to advance healthcare, ensuring compatibility between drug formulations and device components is essential for safety and performance. This webinar provides a focused overview of the key principles behind successful combination product development, emphasizing how drugs and devices interact across the product lifecycle.

Participants will explore critical areas including drug stability in contact with device materials, chemical compatibility and interaction risks, biocompatibility considerations, and microbiological safety. The session will highlight potential risks associated with incompatible components and outline testing strategies used to evaluate and mitigate these challenges.

Attendees will leave with a clear understanding of how to assess compatibility, support regulatory expectations, and ensure consistent product quality. This webinar equips professionals with practical knowledge to design and maintain combination products that deliver safe, reliable, and effective therapeutic outcomes.

Who Should Attend:

  • Pharmaceutical drug manufacturers
  • Medical device manufacturers
  • Packaging, drug compatibility, and quality personnel
  • Regulatory affairs
  • R&D
  • Clinical research, compliance, consulting, drug safety, and validation personnel

 

Presented by PharmTech

21271

Tonya Morris

Global Segment Director, Pharmaceutical Microbiology

Tonya Morris has worked in the medical device and pharmaceutical industries for over 30 years. She is an experienced scientist and a subject matter expert in many fields of testing, including surface disinfection, filtration sterilization validations, aseptic processing, product microbial activity (potency and preservatives), particulate analysis, container closure systems, contact lens regimen tests, test development, failure investigations, and pharmaceutical product assessments. Her primary tenure has been with Nelson Laboratories LLC where she started in bioburden and radiation sterilization. She participates on the Parenteral Drug Association (PDA), is a co-chair for AAMI/ISO WG9, an executive board member for HCPA, and participates on several Kilmer committees. She enjoys partnering with sponsors to develop test methods, consult, assist with product design, review process controls, and problem-solve.

21270

Mark Guevarra

Site Leader

Mark Guevarra is a pharmaceutical industry leader with over 20 years of experience across large pharma, generic drug manufacturers, and contract research organizations. As a Site Leader in Nelson Labs, he leads cross-functional teams across the full drug product lifecycle, from development through commercialization, with deep experience managing multiple business units in CROs and testing laboratories.